key: cord-0788085-zs1sfovn
authors: Wang, J. J.; Zhang, N.; Chen, S.; Wu, J. V.; Yang, X.
title: A lateral flow test detecting SARS-CoV-2 neutralizing antibodies
date: 2020-11-10
journal: nan
DOI: 10.1101/2020.11.05.20222596
sha: b9eb8f7574c6a365bea48fb49c81a1d81bcbd1d1
doc_id: 788085
cord_uid: zs1sfovn

It is of critical importance for COVID-19 survivors, vaccine recipients, and public to know whether they have developed neutralizing antibodies or immunity. Here, we describe a 15 minutes lateral flow test for rapid detection of neutralizing antibodies against SARS-CoV-2. All other currently available neutralization tests require hours or days to complete and have to be performed in a well-equipped laboratory. This lateral flow test is the first of its kind and can serve as a convenient diagnostic tool in management of COVID-19 disease.

Our NAb LFT was designed to have three test lines and one control line (Fig 2A) , using 60 nm Gold Nanoparticle (GNP)-conjugated RBD or S1 protein to display signal, and using ACE2 in strip (T1 line in Fig 2A) to capture GNP if the interaction between RBD and ACE2 was not completely blocked by neutralizing antibodies from a plasma. Two additional test lines showing anti-S1 protein or anti-RBD IgG (T2) and IgM (T3) were included as a positive reading reference for positive specimen.

Using the above 4-line strip, we evaluated NAbs from all 80 patients' plasmas. A single dilution of 1:12 was used for the purpose to match the common practice in the field. Typical in the field, with aid of a lancet, 10 µl of finger blood was taken and transferred into the sample pad of a LFT device, and 50-70ul of buffer was then added to drive the blood sample through the LFT device.

Partial results are demonstrated in Figure 2B . The images of the test results on strips were captured with a smartphone camera and analyzed with Image J software. The intensity of the test line was computed against that of a known negative plasma and presented as inhibition percentage (Supplementary Table 1) . A good correlation was observed between the inhibition percentage at 1:12 dilution of LFT and that of inhibition ELISA (r=0.79, 95% CI: 0.79-0.86, p<0.0001).

RT-PCR or PCR is currently considered as a gold standard in COVID-19 diagnosis and its result is often qualitatively presented as positive and negative. In order to parallelly compare with the qualitative PCR results, we converted all our quantitative results to qualitative positive and negative by using the cutoff established with the 20 normal plasmas for S1 IgG and S1 IgM data and by using 50% inhibition at 1:12 dilution as the cutoff for NAb measurements. A meaningful cutoff for a protective level of NAb should be established through large scale clinical trials, exemplified as IC50 of 1:10 diluted serum for Japanese Encephalitis 19 and 1:22 for Mumps 20 .

The NAb LFT cutoff we adopted here is artificial but within the reference ranges and may need to be updated later.

Correlation of our ELISA and LFT inhibition results versus patient plasma PCR results are shown in Supplementary Table 2-5. In summary, a very good negative percent agreement (90%) was observed between PCR and NAb inhibition assays among PCR negative plasmas (Supplementary Table 1 , 2 and 3). The 3 plasma samples that produced discordant results (negative PCR, but positive NAb inhibition assay) have been repeatedly tested and found to . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2020. ; https://doi.org/10.1101/2020.11.05.20222596 doi: medRxiv preprint contain neutralizing antibody by both inhibition ELISA and NAb LFT, thus should be considered false PCR negatives. One (plasma # N9) of those three has been chosen to demonstrate application of our NAb LFT (Fig. 2D ). In contrast, IgG and IgM against S1 protein showed very poor negative percent agreement with PCR and NAb data (Fig. 1F , Supplementary Table 1, 4 and 5). 53.3% of the 30 PCR negative patients showed S1 IgG and 66.7% showed S1 IgM. It is known that the S and N proteins among all seven human infecting coronaviruses share a significant amount of sequence homology and can induce cross reactive antibody responses. 21 To determine the contributing factor to these high negative percent disagreements, we tested 12 of the 30 PCR negative plasmas against S and N proteins of the 4 common cold coronaviruses, using the same ELISA protocol we used for SARS-CoV-2 proteins. Surprisingly, a higher IgG or IgM level against S or N proteins of at least one of the 4 common cold coronaviruses was observed, compared to that of SARS-CoV-2 among all 12 of the plasmas that were tested.

Representative expression profiles by number 1 and 2 PCR negative plasmas (N1 and N2) are shown in Supplementary Figures 1A to 1D . Based on all of the available data, we believe that a certain percentage of PCR negative results were true false negatives and may be improved by testing patients' neutralizing antibody rather than their binding antibody. Still, we cannot rule out the possibility that some of the patients in this group actually suffered severe infection caused by one of the 4 common cold coronaviruses rather than by SARS-CoV-2.

Using the strip with Positive Control and T1 lines, we demonstrated IC50 measurement of two monoclonal NAbs and three plasmas. In this experiment, a series of dilutions of each NAb or plasma were tested. The results were computed with Image J software and then analyzed and graphed with GraphPad Prism (Fig 2C and 2D ). We also used the same set of patients' plasmas to compare this procedure with inhibition ELISA and a pseudovirus neutralization test (Fig 2E) .

In general, we observed quite comparable IC50 results. Among the three methods, the pseudovirus neutralization test is the most complicated, expensive and lengthy. We used a commercially available pseudovirus and a one-step luciferase detection system, but still needed days of cell culture work before and after ACE2 gene transfection. Inhibition ELISA, on the other hand, has been a routine and standard method in our laboratory, like many other laboratories. It therefore provides a straightforward technical process. But even so, it requires several hours of experimental work and needs to be performed in a laboratory setting. In contrast, the NAb LFT that we've established works in the same way as most other lateral flow . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2020. ; https://doi.org/10.1101/2020.11.05.20222596 doi: medRxiv preprint tests and can be completed within 15 minutes. Besides its convenience and short turnaround time, though, its most prominent advantage might be its nature of flexibility. In other neutralization tests, a negative specimen has to be tested for full dilution range in duplicate or triplicate in order to know the result. Using our LFT, we were able to eliminate all negative specimens after testing a single concentration and then continuously testing specimens with a higher neutralizing antibody titer until their IC50s were captured.

Theoretically, any neutralization assays using live cell and live virus simultaneously measure neutralizing antibodies targeting three regions, N terminal domain (NTD) and RBD in S1and cell fusion domain in S2. LFT and ELISA, without live cell involved and depending on which protein fragment is used, can be used to evaluate NAbs specific to one or two domains in S1 protein. We compared performance of GNP labeled RBD with GNP labeled S1 and indeed found higher NAb titer by using GNP labeled S1 (Supplementary Figure 2) . However, we did not see higher NAb titer in the pseudovirus neutralization test than the other two tests in a small but direct comparison (Fig 2E) .

To combat COVID-19 pandemic, our NAb LFT is continuously improved toward an IVD product. Since a neutralizing antibody result has to be quantitative or semi-quantitative, we anticipate using a smartphone and web-based solution for data capturing and processing. This not only offers convenience, but also necessary quality control for the product. A. Antibody expression profile of PCR negative patient plasma N6 shows no SARS-Cov-2 specific binding antibody and neutralizing antibody developed; B. Antibody expression profile of PCR positive patient plasma P42 represents specimens with moderate level of SARS-Cov-2 antibodies; C. Plasma P7 profile represents a group of specimens with high level of antibody expression against S, N and E proteins and with strong neutralizing activity; D. Distribution of IgG and IgM against S1 protein among different specimen groups, IgG is significantly higher in PCR positive plasmas than in PCR negative plasmas but no difference was seen for IgM. E.

Distributions of S1 IgG and S1 IgM of the 50 PCR positive patients sorted first by IgG and then IgM expression level, only displayed are the those signals above the average plus 2SD of the 20 normal plasmas; F. The same distributions as in Fig. 1E but for PCR negative group, the scale has been adjusted to be the same as Fig. 1E . A few representative specimens were indicated with label and arrow.

A. Schematic structure of the LFT strip constructed in this report and projected results. One representing format used a 60nm GNP labeled RBD with a rabbit Fc tag and accordingly an antirabbit IgG gamma chain antibody in control line. The strip contains three test lines, one for neutralization activity (T1) and the other two for measurement of RBD-specific IgG and IgM respectively (T2 and T3). Another 60nm GNP labeled with S1 protein was also used through the project. B. A manually prepared strip (using adjustable pipette to dispense/coat) demonstrating various levels of inhibition effect by different patient's plasmas. C. Measurement of inhibition concentration of two neutralizing antibodies using 60nm GNP labeled RBD with a rabbit Fc tag and a workflow from 15 min test to IC50 calculation. D. Half-Strip demonstration of 3 plasma samples and the workflow to obtain their IC50. A GNP labeled S1 protein was used in this test.

Inhibitory effects on some control lines were caused by the use of a neutralizing antibody in the control line. E. A comparison of three different inhibition tests, LFT, ELISA and pseudovirus based neutralization test, using one moderate and two strong inhibitory plasma specimens.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2020. ; https://doi.org/10.1101/2020.11.05.20222596 doi: medRxiv preprint Antibodies against S1 protein S1-specific IgG and IgM among 30 PCR negative patients 

WHO. WHO Coronavirus Disease (COVID-19) Dashboard

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of antiinfective drugs for COVID-19. bioRxiv

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Vaccines for Biodefense and Emerging and Neglected Diseases

A systematic review of antibody mediated immunity to coronaviruses

We acknowledge the excellent proofreading and editing by David Beglin, PhD and Stephanie Wang, MD.